0001104659-26-058650
SEC filingQ1 FY2026 operating loss narrowed 30.9% to -$46.1M as early-stage program costs decreased without prior year's one-time collaboration payment, driving 32.7% net loss improvement to -$43.3M and EPS enhancement to -$0.96.
Net loss followed suit, improving 32.7% to -$43.3 million from -$64.4 million, aided by the operating improvements and an increase in interest income stemming from higher average invested balances. Diluted EPS enhanced 49.5% to -$0.96 from -$1.90, underscoring the per-share impact of loss reduction in a clinical-stage biotech context where equity dilution is managed amid funding needs. Net cash provided by operating activities—effectively a reduced use of -$41.9 million versus -$68.0 million prior year—further highlights operational efficiency, as R&D costs are expensed as incurred with prepayments deferred until services are received.